Attempting to learn and process large amounts of complex information after a diagnosis of pancreatic cancer can leave anyone feeling lost. So where should you turn? Start with Patient Central.
Receiving a pancreatic cancer diagnosis can stop a family in their tracks. Not only must patients and their loved ones navigate the emotional impact, but they are often asked to make quick treatment decisions. Attempting to learn and process large amounts of complex information can leave anyone feeling lost.
So where should you turn? Start with Patient Central.
The Pancreatic Cancer Action Network’s Patient Central is the first place to call after a diagnosis of pancreatic cancer or at any point in your journey. Patient Central Associates can help provide information for any question you have about pancreatic cancer. An Associate can also help you navigate the most critical decisions you’ll need to make to:
Contact Patient Central for personalized, one-to-one support from an Associate. All information and services are provided free of charge because of the philanthropy of generous friends.
This article was originally published by the Pancreatic Cancer Action Network. It is republished with permission.
Nivolumab/Chemo Improves Survival in Advanced Gastric/GEJ Cancer
March 14th 2024The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Nivolumab/Chemo Improves Survival in Advanced Gastric/GEJ Cancer
March 14th 2024The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer
Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer
2 Commerce Drive
Cranbury, NJ 08512